- Home
- DMRC vs PVLA Comparison
DMRC vs PVLA Comparison
Compare DMRC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMRC
- PVLA
- Stock Information
- Founded
- DMRC 2008
- PVLA 2015
- Country
- DMRC United States
- PVLA United States
- Employees
- DMRC N/A
- PVLA N/A
- Industry
- DMRC EDP Services
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- DMRC Technology
- PVLA Health Care
- Exchange
- DMRC Nasdaq
- PVLA Nasdaq
- Market Cap
- DMRC 275.4M
- PVLA 285.2M
- IPO Year
- DMRC N/A
- PVLA N/A
- Fundamental
- Price
- DMRC $11.78
- PVLA $37.44
- Analyst Decision
- DMRC Strong Buy
- PVLA Strong Buy
- Analyst Count
- DMRC 1
- PVLA 8
- Target Price
- DMRC $30.00
- PVLA $47.50
- AVG Volume (30 Days)
- DMRC 129.1K
- PVLA 170.3K
- Earning Date
- DMRC 08-14-2025
- PVLA 08-15-2025
- Dividend Yield
- DMRC N/A
- PVLA N/A
- EPS Growth
- DMRC N/A
- PVLA N/A
- EPS
- DMRC N/A
- PVLA N/A
- Revenue
- DMRC $37,848,000.00
- PVLA N/A
- Revenue This Year
- DMRC N/A
- PVLA N/A
- Revenue Next Year
- DMRC $4.21
- PVLA N/A
- P/E Ratio
- DMRC N/A
- PVLA N/A
- Revenue Growth
- DMRC 2.44
- PVLA N/A
- 52 Week Low
- DMRC $10.44
- PVLA $11.17
- 52 Week High
- DMRC $48.32
- PVLA $40.50
- Technical
- Relative Strength Index (RSI)
- DMRC 36.22
- PVLA N/A
- Support Level
- DMRC $12.05
- PVLA N/A
- Resistance Level
- DMRC $12.97
- PVLA N/A
- Average True Range (ATR)
- DMRC 0.51
- PVLA 0.00
- MACD
- DMRC -0.09
- PVLA 0.00
- Stochastic Oscillator
- DMRC 0.33
- PVLA 0.00
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.